First Trust Advisors LP Coherus Bio Sciences, Inc. Transaction History

First Trust Advisors LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$3.74 - $5.45 $102,090 - $148,768	27,297 New	27,297 $102,000
Q3 2021 Nov 15, 2021	SELL	$12.68 - $17.79 $495,699 - $695,464	-39,093 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $682,180 - $811,767	-52,678 Reduced 57.4%	39,093 $541,000
Q1 2021 May 14, 2021	BUY	$14.42 - $21.39 $224,966 - $333,705	15,601 Added 20.48%	91,771 $1.34 Million
Q4 2020 Feb 02, 2021	SELL	$16.56 - $18.94 $212,166 - $242,659	-12,812 Reduced 14.4%	76,170 $1.32 Million
Q3 2020 Nov 05, 2020	BUY	$17.41 - $19.89 $1.55 Million - $1.77 Million	88,982 New	88,982 $1.63 Million
Q1 2020 May 06, 2020	SELL	$11.67 - $22.53 $568,807 - $1.1 Million	-48,741 Closed	0 $0
Q4 2019 Feb 03, 2020	SELL	$16.33 - $21.37 $1.98 Million - $2.59 Million	-121,006 Reduced 71.29%	48,741 $878,000
Q3 2019 Nov 04, 2019	BUY	$16.3 - $23.37 $2.28 Million - $3.27 Million	140,107 Added 472.7%	169,747 $3.44 Million
Q2 2019 Jul 30, 2019	BUY	$13.1 - $22.1 $388,284 - $655,044	29,640 New	29,640 $655,000
Q1 2019 May 09, 2019	SELL	$8.38 - $15.5 $759,605 - $1.4 Million	-90,645 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$8.65 - $16.28 $784,079 - $1.48 Million	90,645 New	90,645 $820,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.